Aminoglutethimide
- Generic Name
- Aminoglutethimide
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16N2O2
- CAS Number
- 125-84-8
- Unique Ingredient Identifier
- 0O54ZQ14I9
- Background
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
- Indication
For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 48
- Registration Number
- NCT06938503
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Jin Xu
- Target Recruit Count
- 46
- Registration Number
- NCT06916975
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, ShangHai, China
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06825546
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06781086
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT06722911
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT06405685
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT06404840
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
- Conditions
- Sepsis
- Interventions
- Drug: intermittent pivotal βL-ABDrug: continuous pivotal βL-AB
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 600
- Registration Number
- NCT05681442
- Locations
- 🇫🇷
Médecine Intensive Réanimation - Hôpital Croix Rousse, Lyon, France
🇫🇷Réanimation Chirurgicale - Saint Eloi, Montpellier, France
🇫🇷Médecine Intensive Réanimation - Pasteur 2, Nice, France
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 30
- Registration Number
- NCT05679050
- Locations
- 🇨🇳
Rui Liu, Tianjin, Tianjin, China
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 32
- Registration Number
- NCT05481476
- Locations
- 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.